螺内酯对急性心肌梗死患者基质金属蛋白酶水平的影响  

The effects of spironolactone on changes of matrix metalloproteinase of patients with acute myocardial infarction

作　　者：甘丰[1] 戴天然 彭良珍[1] 陆惠[1] 王蓉[1] 胡东南[1] 

机构地区：[1]北京航天总医院心内科,100076

出　　处：《中国现代医药杂志》2010年第9期20-22,共3页Modern Medicine Journal of China

摘　　要：目的观察螺内酯对急性心肌梗死(AMI)患者血清基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)水平的影响。方法将68例未经溶栓或者溶栓未成功的AMI患者随机分为常规治疗组(32例)和螺内酯治疗组(36例),持续观察12周。比较24小时内、1周后、4周后、12周后血清基质金属蛋白酶-2和基质金属蛋白酶-9的水平。结果较常规治疗组而言,螺内酯治疗能降低1周及此后的基质金属蛋白酶-2和基质金属蛋白酶-9的水平(P<0.05)。结论螺内酯治疗能够降低心肌梗死后1周以后的基质金属蛋白酶-2和基质金属蛋白酶-9水平。Objective To investigate the effects of spironolactone on changes of matrix metalloproteinase-2（MMP-2） and matrix metalloproteinase-9（MMP-9） of patients with acute myocardial infarction（AMI）.Methods Sixty-eight patients with AMI who without thrombolysis treatment or failure in thrombolysis treatment were divided into usual therapy group（n=32） and spironolactone group（n=36） randomly.MMP-2 and MMP-9 in plasma were measured for 12 weeks.Compared with the levels of MMP-2 and MMP-9 of 1 week and 4 weeks and 12 weeks after AMI.Results Compared to the usual therapy group,the levels of MMP-2 and MMP-9 were siginificantly lower in spironolactone group（P0.05）after intervention for 1 week and later.Conclusion Spironolactone treatment can decrease the levels of MMP-2 and MMP-9 of patients with AMI after intervention for 1 week.

关 键 词：急性心肌梗死 基质金属蛋白酶 螺内酯 

分 类 号：R542.22[医药卫生—心血管疾病]